HemoSense to Present at the Rodman & Renshaw 8th Annual Healthcare Conference
30 Outubro 2006 - 9:00AM
Business Wire
HemoSense, Inc. (AMEX:HEM) today announced that Jim Merselis,
President and CEO, will make an investment community presentation
at the Rodman & Renshaw 8th Annual Healthcare Conference on
Wednesday, November 8 at 11:00 a.m. Eastern time (8:00 a.m. Pacific
time). The conference is being held at The New York Palace Hotel,
New York. A live audio and slide webcast of the presentation will
be available via the Internet by visiting the Investors section of
the Company�s Web site at www.hemosense.com. An archived
presentation will be available on the Web site for 30 days. About
HemoSense HemoSense develops, manufactures and markets easy-to-use,
handheld blood coagulation systems for monitoring patients taking
warfarin. The HemoSense INRatio� system, used by healthcare
professionals and patients themselves, consists of a small monitor
and disposable test strips. It provides accurate and convenient
measurement of blood clotting time, or PT/INR values. Routine
measurements of PT/INR are necessary for the safe and effective
management of the patient�s warfarin dosing. INRatio is sold in the
United States and internationally. For more information, visit
www.hemosense.com. HemoSense� and INRatio� are registered
trademarks of HemoSense, Inc. HemoSense, Inc. (AMEX:HEM) today
announced that Jim Merselis, President and CEO, will make an
investment community presentation at the Rodman & Renshaw 8th
Annual Healthcare Conference on Wednesday, November 8 at 11:00 a.m.
Eastern time (8:00 a.m. Pacific time). The conference is being held
at The New York Palace Hotel, New York. A live audio and slide
webcast of the presentation will be available via the Internet by
visiting the Investors section of the Company's Web site at
www.hemosense.com. An archived presentation will be available on
the Web site for 30 days. About HemoSense HemoSense develops,
manufactures and markets easy-to-use, handheld blood coagulation
systems for monitoring patients taking warfarin. The HemoSense
INRatio(R) system, used by healthcare professionals and patients
themselves, consists of a small monitor and disposable test strips.
It provides accurate and convenient measurement of blood clotting
time, or PT/INR values. Routine measurements of PT/INR are
necessary for the safe and effective management of the patient's
warfarin dosing. INRatio is sold in the United States and
internationally. For more information, visit www.hemosense.com.
HemoSense(R) and INRatio(R) are registered trademarks of HemoSense,
Inc.
Hemosense (AMEX:HEM)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Hemosense (AMEX:HEM)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Hemosense da American Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de HemoSense, Inc.